News
Pfizer beats in Q2 earnings, reaffirms 2025 outlook
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 billion in revenues. The company reported revenues of $14.7 billion, compared to Wall Street expectations of $13.5 billion, and earnings per share of $0.78, versus estimates of $0.58 per share.
14hon MSN
And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...
In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...
Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...
Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...
Pfizer's Albert Bourla told investors that major drugmakers are "ready to to roll up their sleeves" and build out more direct ...
Pfizer ( PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the ...
Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback